Quantification of [18 F]florbetaben amyloid-PET imaging in a mixed memory clinic population. The ABIDE project

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Collij, Lyduine E.
• dc.contributor.author Salvadó, Gemma
• dc.contributor.author de Wilde, Arno
• dc.contributor.author Altomare, Daniele
• dc.contributor.author Shekari, Mahnaz
• dc.contributor.author Domingo Gispert, Juan
• dc.contributor.author Bullich, Santiago
• dc.contributor.author Stephens, Andrew W.
• dc.contributor.author Barkhof, Frederik
• dc.contributor.author Scheltens, Philip
• dc.contributor.author Bouwman, Femke
• dc.contributor.author van der Flier, Wiesje M.
• dc.date.accessioned 2023-02-20T07:49:02Z
• dc.date.available 2023-02-20T07:49:02Z
• dc.date.issued 2022
• dc.description.abstract Introduction: we investigated amyloid-burden quantification in a mixed memory clinic population. Methods: [18 F]Florbetaben amyloid-PET (positron emission tomography) scans of 348 patients were visually read and quantified using the Centiloid (CL) method. General linear models were used to assess CL differences across syndromic and etiological diagnosis. Linear mixed models were fitted to assess the predictive value of visual read (VR) and CL on longitudinal Mini-Mental Status Examination (MMSE). Results: CL was associated with syndromic (F = 4.42, p = 0.014) and etiological diagnosis (F = -12.66, p < 0.001), with Alzheimer's disease (AD) patients showing the highest amyloid burden (62.9 ± 27.5), followed by dementia with Lewy bodies (DLB) (25.3 ± 35.5) and cardiovascular disease (CVD) (16.7 ± 24.5), and finally frontotemporal lobe degeneration (FTLD) (5.0 ± 17.22, t = -12.66, p < 0.001). CL remained predictive of etiological diagnosis (t = -2.41, p = 0.017) within the VR+ population (N = 157). VR was not a significant predictor of MMSE (t = -1.53, p = 0.13) for the SCD population (N = 90), whereas CL was (t = -3.30, p = 0.001). Discussion: the extent of amyloid pathology through quantification holds clinical value, potentially in the context of differential diagnosis as well as prognosis.
• dc.description.sponsorship Research of the Alzheimer Centre Amsterdam is part of the neurodegeneration research program of Amsterdam Neuroscience. The Alzheimer Centre Amsterdam is supported by Stichting Alzheimer Nederland and Stichting VUmc fonds. WMvdF holds the Pasman chair. WMvdF is recipient of the collaboration project ABIDE-clinical utility, which is co-funded by the PPP Allowance made available by health-Holland, Top Sector Life Sciences & Health, to stimulate public-private partnerships and Life Molecular Imaging GmbH (grant no. LSHM18075). WMvdF is recipient of ABOARD, which is a public-private partnership receiving funding from ZonMW (#73305095007), Alzheimer Nederland and Health∼Holland, Topsector Life Sciences & Health (PPP-allowance; #LSHM20106). More than 30 partners contribute to ABOARD. ABIDE has been funded in the context of the Dutch national dementia plan (project number: 733050201). The project leading to this article has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115952. This Joint Undertaking receives the support from the European Union's Horizon 2020 research and innovation programme and EFPIA. This communication reflects the views of the authors and neither the IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.
• dc.format.mimetype application/pdf
• dc.identifier.citation Collij LE, Salvadó G, de Wilde A, Altomare D, Shekari M, Gispert JD, et al. Quantification of [18 F]florbetaben amyloid-PET imaging in a mixed memory clinic population. The ABIDE project. Alzheimers Dement. 2022; 1-11. DOI: 10.1002/alz.12886
• dc.identifier.doi http://dx.doi.org/10.1002/alz.12886
• dc.identifier.issn 1552-5260
• dc.identifier.uri http://hdl.handle.net/10230/55825
• dc.language.iso eng
• dc.publisher Wiley
• dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/115952
• dc.rights This is an open access article under the terms of the Creative Commons Attribution-Non Commercial-No Derivs License http://creativecommons.org/licenses/by-nc/4.0/, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. ©2022 The Authors. Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Amyloid-PET
• dc.subject.keyword Centiloid quantification
• dc.subject.keyword Dementia
• dc.subject.keyword Diagnosis
• dc.subject.keyword Prognosis
• dc.title Quantification of [18 F]florbetaben amyloid-PET imaging in a mixed memory clinic population. The ABIDE project
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion